title: Augmentation in restless legs syndrome patients in Korea.
abstract: OBJECTIVE
  Augmentation has been known as the major complication of long-term dopaminergic treatment of restless legs syndrome (RLS). However, there have been no reports on the prevalence of augmentation in Korea. Thus, we aimed to assess the rate of augmentation and evaluate related factors in Korean RLS patients.
  
  
  METHODS
  Ninety-four idiopathic RLS patients who have been treated over a period of at least 6 months were enrolled. Thirty subjects were treated with a dopamine agonist only, and 64 were treated with a dopamine agonist and alpha two delta ligands. We assessed the clinical characteristics of those RLS subjects and evaluated the rate of augmentation. Augmentation was assessed using the NIH criteria for augmentation by two RLS experts independently.
  
  
  RESULTS
  Eleven subjects (11.7%) were classified as having definitive or highly suggestive clinical indication of augmentation. In comparing the augmentation group with the non-augmentation group, there were no significant differences of baseline clinical characteristics. Four (13.3%) of the dopamine agonists monotherapy group and seven (10.9%) of the combination therapy group were categorized as augmentation. There was no significant difference in the augmentation rate between these two groups.
  
  
  CONCLUSIONS
  We found an 11.7% augmentation rate in Korean RLS subjects. There was no difference in the rate of RLS augmentation between the dopaminergic monotherapy group and the combined treatment group. It may be related with using a similar dosage of dopaminergic drugs.
authors.affiliation: Department of Neurology, Dongsan Medical Center, Keimyung University School of Medicine, 56 Dalseong-ro, Jung-gu, Daegu, 700-712, Korea.
authors.forename: Ji-Ye
authors.initials: JY
authors.lastname: Jeon
authors.forename: Hye-Jin
authors.initials: HJ
authors.lastname: Moon
authors.forename: Mei Ling
authors.initials: ML
authors.lastname: Song
authors.forename: Hochang B
authors.initials: HB
authors.lastname: Lee
authors.forename: Yong Won
authors.initials: YW
authors.lastname: Cho
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use; D052160:Benzothiazoles / Q000009:adverse effects / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D015259:Dopamine Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D000077206:Gabapentin; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D007723:Korea; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D000077487:Pramipexole; D000069583:Pregabalin / Q000009:adverse effects / Q000627:therapeutic use; D012148:Restless Legs Syndrome / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000588:Amines; D052160:Benzothiazoles; D003509:Cyclohexanecarboxylic Acids; D015259:Dopamine Agents; D007211:Indoles; C046649:ropinirole; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000077487:Pramipexole
references.citation: Mov Disord. 2012 Feb;27(2):277-83
references.pmid: 22328464
references.citation: Sleep Med. 2008 Jul;9(5):572-4
references.pmid: 17921065
references.citation: Sleep Med. 2003 Mar;4(2):101-19
references.pmid: 14592341
references.citation: Sleep Med. 2010 Oct;11(9):807-15
references.pmid: 20817595
references.citation: Sleep Med. 2004 Jan;5(1):9-14
references.pmid: 14725821
references.citation: Qual Life Res. 2007 May;16(4):617-24
references.pmid: 17268935
references.citation: Sleep. 2003 Nov 1;26(7):819-21
references.pmid: 14655914
references.citation: Sleep Med. 2009 Jun;10(6):611-5
references.pmid: 19200780
references.citation: J Neurol. 2006 Aug;253 Suppl 4:IV22-8
references.pmid: 16944353
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:326-33
references.pmid: 23103551
references.citation: J Psychosom Res. 2002 Jul;53(1):547-54
references.pmid: 12127170
references.citation: Sleep Med. 2006 Sep;7(6):534
references.pmid: 16931148
references.citation: Am J Med. 2007 Jan;120(1 Suppl 1):S4-S12
references.pmid: 17198769
references.citation: Sleep. 2012 Aug 01;35(8):1039-62
references.pmid: 22851801
references.citation: Sleep Med Rev. 2010 Oct;14(5):339-46
references.pmid: 20219397
references.citation: N Engl J Med. 2014 Feb 13;370(7):621-31
references.pmid: 24521108
references.citation: Sleep. 1996 Apr;19(3):205-13
references.pmid: 8723377
references.citation: J Neurol. 2010 Feb;257(2):230-7
references.pmid: 19756826
references.citation: Sleep Med. 2007 Aug;8(5):520-30
references.pmid: 17544323
references.citation: Sleep Med. 2011 May;12(5):431-9
references.pmid: 21493132